About RyGen Biopharma
  • Who We Are

Transforming Science into Life-Saving Biologics

RyGen Biopharma Pvt. Ltd. is a biotechnology company headquartered in Hyderabad, India, focused on developing affordable and high-quality biologics and biosimilar medicines using advanced recombinant DNA technology. Our pipeline targets key therapeutic areas including diabetes, obesity, oncology supportive care, autoimmune diseases, osteoporosis, and haematological disorders.

With strong expertise in molecular design, process development, clinical research, regulatory science, and manufacturing, RyGen is establishing a cGMP-compliant biologics manufacturing facility to support both clinical and commercial supply. Our portfolio includes GLP-1 therapies, insulin analogues, specialty biologics, and recombinant enzymes aimed at improving access to critical treatments.
At RyGen, we integrate science, technology, and digital infrastructure to accelerate innovation and expand global access to life-saving biologic medicines.

Vision

To become a globally trusted biopharmaceutical company delivering accessible, affordable, and high-quality biologic medicines that improve patient outcomes and expand healthcare access worldwide through innovation.

Mission

To develop and commercialize safe, effective, and high-quality biologics through:

  • Advanced r-DNA innovation
  • Strong scientific execution
  • Patient-first healthcare impact
  • Scalable and cGMP-aligned manufacturing